<--- Back to Details
First PageDocument Content
Hepatology / Rare diseases / Exercise physiology / Neurological disorders / Inborn errors of carbohydrate metabolism / Glycogen storage disease type II / Glycogen / Muscle / Virus / Biology / Medicine / Health
Date: 2010-01-01 11:24:01
Hepatology
Rare diseases
Exercise physiology
Neurological disorders
Inborn errors of carbohydrate metabolism
Glycogen storage disease type II
Glycogen
Muscle
Virus
Biology
Medicine
Health

amda AMDA Conference Call Transcript Session No. 4: Speaker:

Add to Reading List

Source URL: amdapompe.ehclients.com

Download Document from Source Website

File Size: 248,16 KB

Share Document on Facebook

Similar Documents

Medicine / Health / Clinical medicine / Rare diseases / Porphyrias / Lysosomal storage diseases / RTT / Erythropoietic protoporphyria / Glycogen storage disease type II / Disease

How one patient with a rare disease coped with his genetic disorder

DocID: 1r9mW - View Document

Clinical medicine / Neurochemistry / Medicine / Sodium channel blockers / Alglucosidase alfa / Calcium channel blockers / Glycogen storage disease type II / Ketamine / Treprostinil / Eptifibatide

LUMIZYME (alglucosidase alfa) for Injection

DocID: 1qeuI - View Document

United States patent law / BioMarin Pharmaceutical / Genzyme / Glycogen storage disease type II / Inter partes review / Pharmaceutical drug / Reexamination / Patent Trial and Appeal Board / Inter partes / Iduronidase

United States Court of Appeals for the Federal Circuit ______________________ GENZYME THERAPEUTIC PRODUCTS LIMITED PARTNERSHIP,

DocID: 1oYEH - View Document

Pompe  disease  (Glycogen  storage  disease  type  II) Glycogen  storage  disease  type  II  is  also  known  as  acid  maltase  deficiency  or  generalized  gl

DocID: 1lJGD - View Document

Genetic genealogy / BioMarin Pharmaceutical / Glycogen storage disease type II / Acid alpha-glucosidase / Lysosomal storage disease / Mucopolysaccharidosis / Alglucosidase alfa / Neuronal ceroid lipofuscinosis / Tetrahydrobiopterin / Health / Rare diseases / Medicine

May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

DocID: 1aiEg - View Document